More About the PIA-Study
The PIA-Study will test a potential new treatment called Probucol that was previously used to treat cardiovascular disease and stroke. Scientists have discovered that probucol may be able to support memory performance in Alzheimer's disease.
The aim of this trial is to understand whether or not treatment with Probucol supports memory and thinking skills in participants with mild-dementia due to Alzheimer's disease. The trial is specifically designed to provide evidence that treatment with Probucol may slow the decline of cognitive ability and functional state.
What are the main steps in the clinical trial?
This clinical trial involves 104-weeks (2 years) of repeat daily oral dosing of the study drug.
The total maximum study duration for participants in this study is 112 weeks (2 years and 8 weeks), including the screening period and follow-up visit.
You will be screened to determine your suitability to take part in the study within 24 days before receiving a dose of the study drug.
In this trial, you will receive either Probucol or placebo. A placebo is a medication with no active ingredients and thus has no clinical effect. It looks like the real thing but is not.
You will be allocated to receive either the study drug or the placebo drug using a computer-generated schedule. To avoid accidentally influencing the tests performed in the trial, neither you nor the researchers will know which study medication you were assigned to, but don’t worry, this information can be obtained in case of an emergency. Neither you nor the study doctor can choose what you receive.
You will need to attend 14 clinic visits and receive 7 phone calls over the 2 year period.
There are no overnight confinement periods for this clinical trial.
Visits will range from 1 - 3 hours depending on the visit schedule. Visits may contain the following;
Medical and Disease history
Assessment of Alzheimer’s Disease
Physical and Neurological examination
Vital sign measurements
Additionally, in order for you to participate in this study, a partner/spouse/carer is required to also consent to the minimum requirements of attending at least one screening visit, complete a questionnaire, and being available via phone or in person to provide information as required, for the duration of the study.
For more detailed information about the clinical trial, please click the link below for the study participant information sheet.
Alternatively, if you would like to speak with a member of the research team, please click the link 'Contact Us' for contact information.
Meet our multi-disciplinary team of researchers and clinicians contributing world-class research and clinical expertise to the clinical trial.
Associate Professor Roger Clarnette
Medical Director at the Australian Alzheimer's Research Foundation, Roger is a renowned geriatrician and one of Australia's most experienced clinical trialists in Alzheimer's. Roger is the prinicpal overseer of the PIA study clinical trial, providing clinical leadership and direction.